Gene Expression Profiling for Lung Cancer Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for lung cancer are invasive, costly, and often lead to unnecessary procedures due to the inability to accurately differentiate between cancerous and benign lung nodules, resulting in delayed potential curable therapy and increased anxiety for patients.
Innovation Solution
A composition or kit that includes polynucleotides or oligonucleotides that hybridize to specific genes in a patient sample, allowing for the detection of changes in gene expression profiles to distinguish between cancerous and non-cancerous tumors, using a non-invasive blood test that compares gene expression levels to a reference profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive biopsy or surgery is used to differentiate lung nodules, then diagnostic accuracy is improved, but patient trauma and procedural risk increase
Solution Approach 1:
The patent uses gene expression profiling of circulating tumor cells (CTCs) in blood as an intermediary diagnostic method. Instead of directly invading the lung tissue through biopsy, the test analyzes genetic material from tumor cells that have naturally detached and entered the bloodstream, providing diagnostic information about the lung nodule without direct physical invasion of the target organ.
Solution Approach 2:
The patent replaces the mechanical invasive procedure of biopsy with a molecular diagnostic approach. Instead of physically removing tissue samples through surgical instruments, the method uses molecular analysis of circulating tumor cell gene expression profiles to obtain diagnostic information, substituting mechanical tissue sampling with biochemical analysis of circulating biomarkers.
2Measurement precision
If serial CT scanning is used to monitor indeterminate nodules, then diagnostic monitoring is improved, but radiation exposure and cost increase
Solution Approach 1:
The patent extracts diagnostic information from circulating tumor cells in the bloodstream rather than repeatedly imaging the lung nodule itself. By analyzing gene expression profiles of CTCs that shed into circulation, the method obtains molecular diagnostic data without the need for repeated ionizing radiation exposure from serial CT scans.
Solution Approach 2:
The patent uses circulating tumor cells as intermediary biomarkers to monitor disease status. Instead of directly imaging the lung nodule multiple times with radiation, the test analyzes genetic material from CTCs that naturally circulate in the blood, providing monitoring information through a non-radiative intermediary pathway.
3Measurement precision
If invasive bronchoscopy is used to harvest epithelial cells for testing, then diagnostic accuracy is improved, but procedural complexity and patient discomfort increase
Solution Approach 1:
The patent utilizes circulating tumor cells that naturally detach from the primary tumor and enter the bloodstream without requiring active harvesting procedures. The body's own physiological processes of cell shedding and circulation provide the diagnostic sample automatically, eliminating the need for invasive cell collection procedures like bronchoscopy.
Solution Approach 2:
The patent replaces the mechanical cell harvesting process of bronchoscopy with a molecular analysis approach using circulating tumor cells. Instead of mechanically navigating instruments through the airways to collect epithelial cells, the method analyzes gene expression from CTCs that are already present in the peripheral blood, substituting complex mechanical sampling with simpler blood draw and molecular analysis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection of lung cancer with high sensitivity and specificity, reducing unnecessary procedures and improving patient outcomes by providing a simple, cost-effective method for diagnosing lung cancer through gene expression profiling in blood samples.
Implementation Method 1
a composition or kit for diagnosing or evaluating a lung cancer in a mammalian subject includes ten (10) or more polynucleotides or oligonucleotides, wherein each polynucleotide or oligonucleotide hybridizes to a different gene, gene fragment, gene transcript or expression product in a patient sample
Data Source
AI summary
Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of 10 or more selected genes, e.g., a gene expression profile, from the blood of the subject which is characteristic of disease. The gene expression profile includes 10 or more genes of Table I or Table II herein.